{"transactions":[{"id":893770,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88080,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-05","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893769,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":1.8,"value":10800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction."}],"balance_after":393075,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893768,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":29.5944,"value":65107.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":387075,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893767,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":5400,"price":28.9497,"value":156328.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":389275,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893766,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":28.0211,"value":25218.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":394675,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":919700,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:09:59.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":103000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001193125-26-037570","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526037570/ownership.xml","form_type":"4"}},{"id":937428,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-16T16:06:03.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":200,"price":27.4,"value":5480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."}],"balance_after":395575,"source":{"system":"sec-edgar","filing":"0001193125-26-015350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526015350/ownership.xml","form_type":"4"}},{"id":937427,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-16T16:06:03.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":8300,"price":26.8255,"value":222651.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.33 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":395775,"source":{"system":"sec-edgar","filing":"0001193125-26-015350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526015350/ownership.xml","form_type":"4"}},{"id":952208,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:20:05.000Z","date":"2025-12-31","kind":"sale","planned":false,"acquired":false,"shares":6567,"price":30.0499,"value":197337.6933,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":404075,"source":{"system":"sec-edgar","filing":"0001193125-26-002470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526002470/ownership.xml","form_type":"4"}},{"id":952207,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:20:05.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025."}],"balance_after":410642,"source":{"system":"sec-edgar","filing":"0001193125-26-002470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526002470/ownership.xml","form_type":"4"}},{"id":967916,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T17:07:08.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":796,"price":30.6772,"value":24419.0512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":392642,"source":{"system":"sec-edgar","filing":"0001193125-25-321142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525321142/ownership.xml","form_type":"4"}},{"id":967915,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T17:07:08.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":7704,"price":29.9469,"value":230710.9176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":393438,"source":{"system":"sec-edgar","filing":"0001193125-25-321142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525321142/ownership.xml","form_type":"4"}},{"id":996130,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-18T16:24:43.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":5344,"price":25.3922,"value":135695.9168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":401142,"source":{"system":"sec-edgar","filing":"0001193125-25-286212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525286212/ownership.xml","form_type":"4"}},{"id":996129,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-18T16:24:43.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":3156,"price":24.8399,"value":78394.7244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":406486,"source":{"system":"sec-edgar","filing":"0001193125-25-286212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525286212/ownership.xml","form_type":"4"}},{"id":1017716,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-16T16:30:05.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":1082,"price":26.1641,"value":28309.5562,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":409642,"source":{"system":"sec-edgar","filing":"0001193125-25-241475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525241475/ownership.xml","form_type":"4"}},{"id":1017715,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-16T16:30:05.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":7418,"price":25.7329,"value":190886.6522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":410724,"source":{"system":"sec-edgar","filing":"0001193125-25-241475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525241475/ownership.xml","form_type":"4"}},{"id":1038176,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-17T16:15:10.000Z","date":"2025-09-15","kind":"sale","planned":true,"acquired":false,"shares":3402,"price":24.6583,"value":83887.5366,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.42 to $24.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":418142,"source":{"system":"sec-edgar","filing":"0001193125-25-206203","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525206203/ownership.xml","form_type":"4"}},{"id":1038175,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-17T16:15:10.000Z","date":"2025-09-15","kind":"sale","planned":true,"acquired":false,"shares":5098,"price":23.8841,"value":121761.1418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.42 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":421544,"source":{"system":"sec-edgar","filing":"0001193125-25-206203","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525206203/ownership.xml","form_type":"4"}},{"id":1064213,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-18T17:14:19.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":200,"price":15.79,"value":3158.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.74 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":426642,"source":{"system":"sec-edgar","filing":"0000950170-25-109838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025109838/ownership.xml","form_type":"4"}},{"id":1064212,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-18T17:14:19.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":8300,"price":14.9769,"value":124308.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":426842,"source":{"system":"sec-edgar","filing":"0000950170-25-109838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025109838/ownership.xml","form_type":"4"}},{"id":1086739,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-16T16:14:04.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":13.9955,"value":118961.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.565 to $14.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":435142,"source":{"system":"sec-edgar","filing":"0000950170-25-096268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025096268/ownership.xml","form_type":"4"}},{"id":1106614,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-18T16:15:07.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":11.0026,"value":93522.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.67 to $11.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":443642,"source":{"system":"sec-edgar","filing":"0000950170-25-087897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025087897/ownership.xml","form_type":"4"}},{"id":1143243,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-05-19T16:30:28.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":9.5602,"value":81261.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.19 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":452142,"source":{"system":"sec-edgar","filing":"0000950170-25-074409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025074409/ownership.xml","form_type":"4"}},{"id":1171127,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-16T17:00:04.000Z","date":"2025-04-15","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":9.5659,"value":81310.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.18 to $10.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":460642,"source":{"system":"sec-edgar","filing":"0000950170-25-054819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025054819/ownership.xml","form_type":"4"}},{"id":1204248,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-17T17:00:04.000Z","date":"2025-03-14","kind":"sale","planned":true,"acquired":false,"shares":8500,"price":10.8477,"value":92205.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.42 to $11.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":469142,"source":{"system":"sec-edgar","filing":"0000950170-25-040447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025040447/ownership.xml","form_type":"4"}},{"id":1285323,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T17:30:06.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-013752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017025013752/ownership.xml","form_type":"4"}},{"id":1485301,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T19:43:01.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":28302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":28302,"derivative":{"exercise_price":17,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":28302},"source":{"system":"sec-edgar","filing":"0000950170-24-071539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000095017024071539/ownership.xml","form_type":"4"}}]}